No headlines found.
Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026
ACCESS Newswire (Thu, 9-Apr 1:40 PM ET)
Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy
ACCESS Newswire (Mon, 30-Mar 10:55 AM ET)
Champions Oncology Reports Revenue of $16.6 Million
ACCESS Newswire (Thu, 12-Mar 4:01 PM ET)
Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 12, 2026
ACCESS Newswire (Thu, 5-Mar 4:00 PM ET)
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
Champions Oncology trades on the NASDAQ stock market under the symbol CSBR.
As of April 20, 2026, CSBR stock price declined to $5.99 with 3,571 million shares trading.
CSBR has a market cap of $83.18 million. This is considered a Micro Cap stock.
Last quarter Champions Oncology reported $17 million in Revenue and $.04 earnings per share. This fell short of revenue expectation by $-54,000 and missed earnings estimates by -$.05.
In the last 3 years, CSBR traded as high as $11.99 and as low as $3.60.
The top ETF exchange traded funds that CSBR belongs to (by Net Assets): VTI, VXF, IWC, DCOR, DFSU.
CSBR has underperformed the market in the last year with a price return of -24.8% while the SPY ETF gained +35.6%. CSBR has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -16.9% and +3.8%, respectively, while the SPY returned +2.4% and +7.8%, respectively.
CSBR support price is $5.75 and resistance is $6.33 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CSBR shares will trade within this expected range on the day.